Evidence map›Paper›PMID 38654065›Full record

ArticleScientific reports2024

Catalytic specificity and crystal structure of cystathionine γ-lyase from Pseudomonas aeruginosa.

Marco Pedretti, Carmen Fernández-Rodríguez, Carolina Conter, Iker Oyenarte, Filippo Favretto, Adele di Matteo, Paola Dominici, Maria Petrosino, Maria Luz Martinez-Chantar, Tomas Majtan and 2 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
3.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 3 countries.

Marco Pedretti *Department of Biotechnology, University of Verona, Strada Le Grazie 15, 37134, Verona, Italy.
Carmen Fernández-Rodríguez *Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Building 801A, 48160, Derio, Spain.
Carolina ConterDepartment of Biotechnology, University of Verona, Strada Le Grazie 15, 37134, Verona, Italy.
Iker OyenarteCenter for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Building 801A, 48160, Derio, Spain.
Filippo FavrettoDepartment of Biotechnology, University of Verona, Strada Le Grazie 15, 37134, Verona, Italy.
Adele di MatteoCNR Institute of Molecular Biology and Pathology, P.le Aldo Moro 5, 00185, Rome, Italy.
Paola DominiciDepartment of Biotechnology, University of Verona, Strada Le Grazie 15, 37134, Verona, Italy.
Maria PetrosinoDepartment of Pharmacology, Faculty of Science and Medicine, University of Fribourg, Chemin du Musee 18, Bldg. PER17, 1700, Fribourg, FR, Switzerland.
Maria Luz Martinez-ChantarCenter for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Building 801A, 48160, Derio, Spain.
Tomas MajtanDepartment of Pharmacology, Faculty of Science and Medicine, University of Fribourg, Chemin du Musee 18, Bldg. PER17, 1700, Fribourg, FR, Switzerland.
Alessandra AstegnoDepartment of Biotechnology, University of Verona, Strada Le Grazie 15, 37134, Verona, Italy. alessandra.astegno@univr.it.
Luis Alfonso Martínez-CruzCenter for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Building 801A, 48160, Derio, Spain. amartinez@cicbiogune.es.
CIC bioGUNE · ESUniversity of Verona · ITUniversity of Fribourg · CHCentro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas · ESInstitute of Molecular Biology and Pathology · IT

Funding

Italian Ministry of University and Research MUR-PRIN 2022 20224BYR59Ministerio de Ciencia, Innovación y Universidades PID2020-117116RB-I00 CEX2021-001136-SSpanish Ministerio de Ciencia e Innovación (MICINN) PID2019-109055RB-I00Spanish Ministry of Economy and Competitiveness BFU2016-77408-RUniversity of Fribourg Research Pool grant 22-15
6 · The paper itself

Abstract

The escalating drug resistance among microorganisms underscores the urgent need for innovative therapeutic strategies and a comprehensive understanding of bacteria's defense mechanisms against oxidative stress and antibiotics. Among the recently discovered barriers, the endogenous production of hydrogen sulfide (H

Indexed as

Catalytic DomainCystathionine gamma-LyaseHydrogen SulfidePseudomonas aeruginosaBacterial ProteinsCatalysisCrystallography, X-RayCysteineHomocysteineHumansModels, MolecularProtein ConformationSubstrate SpecificityBacterial ProteinsCystathionine gamma-LyaseCysteineHomocysteineHydrogen SulfideCatalytic specificityCrystal structureCystathionine γ-lyaseHydrogen sulfideMultidrug resistant bacteriaPseudomonas aeruginosa

Identifiers

PMID38654065
PMCPMC11039470
OpenAlexW4395030049

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.